Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) FCF Margin % : -67.12% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Ultragenyx Pharmaceutical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ultragenyx Pharmaceutical's Free Cash Flow for the three months ended in Dec. 2023 was $-85.5 Mil. Ultragenyx Pharmaceutical's Revenue for the three months ended in Dec. 2023 was $127.4 Mil. Therefore, Ultragenyx Pharmaceutical's FCF Margin % for the quarter that ended in Dec. 2023 was -67.12%.

As of today, Ultragenyx Pharmaceutical's current FCF Yield % is -14.61%.

The historical rank and industry rank for Ultragenyx Pharmaceutical's FCF Margin % or its related term are showing as below:

RARE' s FCF Margin % Range Over the Past 10 Years
Min: -128693.98 Med: -250.95 Max: -64.98
Current: -120.11

During the past 13 years, the highest FCF Margin % of Ultragenyx Pharmaceutical was -64.98%. The lowest was -128693.98%. And the median was -250.95%.

RARE's FCF Margin % is ranked better than
52.61% of 1036 companies
in the Biotechnology industry
Industry Median: -148.935 vs RARE: -120.11

Ultragenyx Pharmaceutical FCF Margin % Historical Data

The historical data trend for Ultragenyx Pharmaceutical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical FCF Margin % Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-356.96

-64.98

-117.18

-144.93

-120.11

Ultragenyx Pharmaceutical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-113.51	-181.00	-122.43	-123.98	-67.12

Competitive Comparison of Ultragenyx Pharmaceutical's FCF Margin %

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ultragenyx Pharmaceutical's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's FCF Margin % falls into.

Ultragenyx Pharmaceutical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ultragenyx Pharmaceutical's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-521.573	/	434.249
	=	-120.11 %

Ultragenyx Pharmaceutical's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-85.504	/	127.392
	=	-67.12 %

Ultragenyx Pharmaceutical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

RARE:Mexico UP0:Germany

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Executives

Emil D Kakkis	director, 10 percent owner, officer: President & CEO	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Thomas Richard Kassberg	officer: CBO & Senior Vice President	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Howard Horn	officer: Chief Financial Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Theodore Alan Huizenga	officer: Controller and PAO	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Erik Harris	officer: EVP & Chief Commercial Officer	60 LEVERONI COURT, NOVATO CA 94949
Sanders Corazon (corsee) D.	director	C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
John Richard Pinion	officer: See Remarks	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Karah Herdman Parschauer	officer: EVP and General Counsel	60 LEVERONI COURT, NOVATO CA 94949
Eric Crombez	officer: EVP and Chief Medical Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Dennis Karl Huang	officer: SVP and Chief Tech Ops Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Camille L Bedrosian	officer: EVP and Chief Medical Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Mardi Dier	officer: CFO & Executive Vice President	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Amrit Ray	director	60 LEVERONI COURT, NOVATO CA 94949
William Aliski	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Shalini Sharp	officer: CFO & Senior Vice President	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949